TERN

Terns Pharmaceuticals, Inc. (TERN) | Rumor.io

Terns Pharmaceuticals

TERN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)87%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TERN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% +0	0% 0

Mar 27

Terns Pharmaceuticals ($TERN) announced a $6.7 billion acquisition by Merck ($MRK) for TERN-701, an allosteric modulator.
Tern's leading obesity drug failed, but the company's cancer vaccine, GPS, has shown promising results with a potential global TAM of $10B+.
Tern's GPS has the potential to be a best-in-class therapy for both CR1 and CR2, with long mOS and a potentially large market share in the US alone.

Generated by AI

Sentiment

Of the messages about TERN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% 0	73.98% -7.12
Bearish	0% 0	0%	0% 0	26.02% +7.12

Bullish· Mar 25

Terns Pharmaceuticals ($TERN) has seen a significant price increase from $2 in April 2025 to $57, making it an attractive investment opportunity.
The acquisition of Terns Pharmaceuticals by Merck ($MRK) for $6.7 billion could have a positive impact on the company's stock price and boost its cancer drug pipeline.
The $6.7 billion deal value for Terns Pharmaceuticals ($TERN) may be undervalued, considering the company's potential and the fact that some analysts predicted a higher bid.

Bearish· Nov 5

The market expects Terns Pharmaceuticals to post a loss of $0.32 per share for the quarter, worse than the previous quarter.
The company's phase 2 costs are expected to be hundreds of millions of dollars, and phase 3 costs will be billions of dollars, which it may not have, leading to further dilution.
Terns Pharmaceuticals has a history of failing, with its previous asset TERN-601 being a complete failure, and its current asset TERN-701 may also fail, leading to a potential price drop to $1.

Generated by AI

Topics

Of the messages about TERN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	9.44%
Announcements	—	—	100%	78.85%
Controversies	—	—	0%	0.31%
Earnings	—	—	0%	0.34%
Macro	—	—	0%	3.82%
Technical Analysis	—	—	0%	7.23%

Mar 25

Merck is acquiring Terns Pharmaceuticals for $6.7 billion, with Terns' shares rising approximately 10% in after-hours trading.
The acquisition is an all-cash deal, with Merck paying $53.00 per share, and is expected to be accounted for as an asset acquisition, resulting in a charge of approximately $5.8 billion.
The deal strengthens Merck's cancer pipeline, particularly with Terns' novel candidate for chronic myeloid leukemia (CML), TERN-701, and comes as Merck prepares for the patent expiry of its blockbuster drug Keytruda in 2028.

Generated by AI

Community

Of the messages about TERN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	77.23%	54.09%
Newcomers	—	100%	22.77%	45.91%

Regulars· Dec 10

$TERN stock surged 460% from early November, driven by Phase 1 CML efficacy data and a 64% MMR achievement by 24 weeks in a refractory patient population.
Analysts have raised their price targets for Terns Pharmaceuticals, with HC Wainwright setting a target of $60, Oppenheimer at $58, Truist at $56, Barclays at $56, Mizuho at $54, and BMO at $54.
Terns Pharmaceuticals priced an upsized $650 million public offering at $40 per share, issuing 16.25 million shares into the market, with a 30-day option for an additional 2.44 million shares.

Newcomers· Mar 13

Terns Pharmaceuticals, Inc. (TERN) could be a takeover target, potentially reaching $69 per share.
Zacks Investment Research has highlighted TERN as one of four biotech stocks with upside potential for 2026, citing strong portfolio positioning and solid pipeline progress.
A market maker is expecting significant trading volume at $50, which could be reached this afternoon.

Generated by AI

Also Discussed

Investors talking about TERN also mention

#	Name	Attention
1	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
2	MTSR - Metsera, Inc.	——
3	ETNB - 89bio, Inc.	——
4	Viking Therapeutics, Inc.VKTX	0.18%0
5	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
6	Altimmune, Inc.ALT	0.04%-0.01
7	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	VTYX - Ventyx Biosciences, Inc.	——
10	Rhythm Pharmaceuticals, Inc.RYTM	0%0